Irritable Bowel Syndrome News

Prometheus Laboratories has announced the launch of a new test called IBcause that simultaneously evaluates 20 stool and serum measures to help diagnose many common causes of persistent diarrhea.

Synergy Pharmaceuticals announced it has submitted a supplemental New Drug Application to the FDA for Trulance for the treatment of adults with constipation-predominant irritable bowel syndrome.

The FDA has issued a safety announcement warning that Viberzi should not be used in patients who do not have a gallbladder due to an increased risk for serious pancreatitis.

Symptoms related to diarrhea-predominant irritable bowel syndrome significantly impact quality of life, yet a substantial proportion of individuals who meet criteria for IBS-D remain undiagnosed and untreated, according to the results of an online survey.

Acupuncture improved symptoms in patients with irritable bowel syndrome that were statistically superior to standard of care through 1 year, but ceased to be significantly superior at 2 years, according to the results of a randomized controlled trial.

Researchers have identified an intestinal microbiota signature associated with severity of symptoms in irritable bowel syndrome.

Axim Biotechnologies has initiated a clinical trial of its non-prescription hemp-derived cannabinoid functional chewing gum for the treatment of patients with irritable bowel syndrome.

Evidence on the effectiveness of cannabis and cannabinoids for the treatment of irritable bowel syndrome is insufficient, and represents a significant research gap that should be addressed by diverse stakeholders, according to a new report from the National Academies of Sciences, Engineering, and Medicine released yesterday.

Allergan has entered a research, development, collaboration and license agreement for global rights to Assembly Bioscience’s GI microbiome development programs, which includes two preclinical compounds for ulcerative colitis and Crohn’s disease, and two future compounds for irritable bowel syndrome.

More than a quarter of children with inflammatory bowel disease had an overlapping functional abdominal pain disorder in a recent study.